Abstract:Remodeling is essential for bone health. It begins with resorption of old bone by osteoclasts, followed by the formation of new bone by osteoblasts. Remodeling is coupled (formation is linked to resorption). After middle age or perhaps beginning earlier, bone loss occurs because resorption exceeds formation. This imbalance is accentuated by estrogen deficiency as well as by many diseases and conditions. Biochemical markers that reflect remodeling and can be measured in blood or urine include resorption markers (e.g., collagen cross-links) and formation markers (e.g., alkaline phosphatase). Bone markers exhibit substantial short-term and long-term fluctuations related to time of day, phase of the menstrual cycle, and season of the year, as well as diet, exercise, and anything else that alters bone remodeling. These biological factors, in addition to assay imprecision, produce significant intra- and interindividual variability in markers. Bone marker measurements are noninvasive, inexpensive, and can be repeated often. Unfortunately, most of the studies that provided insight on clinical situations did not focus on markers as a primary endpoint. Bone markers have been useful in clinical practice and have been helpful in understanding the pathogenesis of osteoporosis and the mechanism of action of therapies. In clinical trials, markers aid in selecting optimal dose and in understanding the time course of onset and resolution of treatment effect. Clinical questions that might be answered by bone markers include diagnosing osteoporosis, identifying "fast bone losers" and patients at high risk of fracture, selecting the best treatment for osteoporosis, and providing an early indication of the response to treatment. Additional information is needed to define specific situations and cut points to allow marker results to be used with confidence in making decisions about individual patients.

Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives

Research and Application of Target Therapy for Osteoporosis

Clinical value of bone turnover markers in the management of osteoporosis

Research Progress in the Laboratory Examination of Biomarkers Associated with Osteoporosis

Novel Biomarkers of Bone Metabolism

Advances in Bone Turnover Markers (PINP and CTX) in Optimizing Anti-resorptive and Anabolic Therapies Against Osteoporosis

An updated overview of the search for biomarkers of osteoporosis based on human proteomics

Clinical utility of biochemical markers of bone remodeling

[Clinical usefulness of bone turnover markers in the management of osteoporosis]

Practical Considerations for the Clinical Application of Bone Turnover Markers in Osteoporosis

Recent progress in bone imaging for osteoporosis research

Insight into the potential of bone turnover biomarkers: integration in the management of osteoporosis and chronic kidney disease-associated osteoporosis

Proteomics in Bone Research

Biochemical markers for assessment of calcium economy and bone metabolism: application in clinical trials from pharmaceutical agents to nutritional products

The Regulatory Roles of MicroRNAs in Bone Remodeling and Perspectives as Biomarkers in Osteoporosis.

Recent advances in bone-targeted therapy

Osteoporosis: integrating biomarkers and other diagnostic correlates into the management of bone fragility

Comparative analysis of bone turnover markers in bone marrow and peripheral blood: implications for osteoporosis

Advances in bone imaging for osteoporosis

New Emerging Biomarkers for Bone Disease: Sclerostin and Dickkopf-1 (DKK1)

Novel Imaging Modalities in Osteoporosis Diagnosis and Risk Stratification